Recombinant Staphylococcal Antigen-F (r-ScaF), a novel vaccine candidate against methicillin resistant Staphylococcus aureus infection: Potency and efficacy studies

Area of Science:

• Microbiology
• Immunology
• Vaccinology

Background:

• Staphylococcus aureus poses a significant threat due to multi-drug resistant strains.
• Antibiotic resistance necessitates novel therapeutic strategies, including immunotherapies.
• Surface components of S. aureus are potential targets for immune interventions.

Purpose of the Study:

• To evaluate the efficacy of a novel staphylococcal conserved antigen family (ScaF) protein as a vaccine candidate.
• To assess the ability of recombinant ScaF (r-ScaF) to elicit cellular and humoral immune responses.
• To determine the protective potential of r-ScaF against S. aureus infection.

Main Methods:

• Mice were immunized with r-ScaF formulated with Freund's or alum adjuvants.
• Immunized mice were challenged with S. aureus in a sepsis model.
• Cellular cytokine responses (IFN-γ, IL-17) and antibody production (IgG subclasses) were measured.
• Mortality rates and bacterial burden in internal organs were assessed.

Main Results:

• Vaccine formulations induced robust cellular immune responses, including IFN-γ and IL-17.
• Humoral immunity showed increased production of IgG2a.
• Active immunization with r-ScaF significantly decreased mortality in infected mice.
• A lower bacterial burden was observed in the internal organs of immunized mice compared to controls.

Conclusions:

• Recombinant ScaF (r-ScaF) effectively elicits protective immune responses against S. aureus.
• r-ScaF demonstrates potential as a prophylactic vaccine component.
• This study supports the consideration of r-ScaF in a multivalent vaccine strategy against S. aureus infections.